As of June 18, 2025, Allakos Inc (ALLK) reports a Gross Margin of 7775.20%.
Gross Margin indicates the portion of sales revenue remaining after covering production costs, highlighting operational efficiency.
Comparing Allakos Inc's Gross Margin to Peers
To better understand Allakos Inc's position, it's useful to compare its Gross Margin against industry peers. Below are selected comparisons:
| Company | Gross Margin |
|---|---|
| Allakos Inc (ALLK) | 7775.20% |
| Zentalis Pharmaceuticals Inc (ZNTL) | 7775.20% |
| Morphic Holding Inc (MORF) | 7775.20% |
| Editas Medicine Inc (EDIT) | 7775.20% |
| Neoimmunetech Inc (950220.KQ) | 7775.20% |
| Xencor Inc (XNCR) | 7775.20% |
Compared to its competitors, Allakos Inc's Gross Margin is higher than all peers, indicating superior product pricing power or cost efficiency in production.